Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Src‐homology 2 domain–containing phosphatase 2 (Shp2) has been reported to play an important role in the maintenance and self‐renewal of embryonic and adult stem cells, but its role in cancer stem cells (CSCs) remains obscure. Herein, we observed high expression of Shp2 in both chemoresistant hepatocellular carcinomas (HCCs) and recurrent HCCs from patients. A remarkable increase of Shp2 was detected in sorted epithelial cell adhesion molecule–positive or cluster of differentiation 133–positive liver CSCs and in CSC‐enriched hepatoma spheroids from patients. Up‐regulated Shp2 facilitated liver CSC expansion by promoting the dedifferentiation of hepatoma cells and enhancing the self‐renewal of liver CSCs. Mechanistically, Shp2 dephosphorylated cell division cycle 73 in the cytosol of hepatoma cells, and the dephosphorylated cell division cycle 73 bound β‐catenin and facilitated the nuclear translocation of β‐catenin, which promoted the dedifferentiation of hepatoma cells. Shp2 increased β‐catenin accumulation by inhibiting glycogen synthase kinase 3β–mediated β‐catenin degradation in liver CSCs, thereby enhancing the self‐renewal of liver CSCs. Blockage of β‐catenin abolished the discrepancy in liver CSC proportion and the self‐renewal capacity between Shp2‐depleted hepatoma cells and control cells, which further confirmed that β‐catenin is required in Shp2‐promoted liver CSC expansion. More importantly, HCC patients with low Shp2 levels benefited from transcatheter arterial chemoembolization or sorafenib treatment, but patients with high Shp2 expression did not, indicating the significance of Shp2 in personalized HCC therapy. Conclusion: Shp2 could promote HCC cell dedifferentiation and liver CSC expansion by amplifying β‐catenin signaling and may be useful in predicting patient response to chemotherapeutics. (H epatology 2017;65:1566‐1580).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Serag, H. B. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1001683 · Cited by 3,529
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249 · cited 1×
“Shp2 acts as a transducer of extracellular pro-survival and proliferative signals, and is required for the full activation of ERK signaling (9).”
BackgroundMYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874 · cited 1×
“Consistently, c-Myc, the major target gene of b-catenin, is closely associated with stemness regulation and might serve as a switch for HCC progression or differentiation.((49,50)) Holczbauer et al.”
BackgroundActivation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
Yamashita, T., Budhu, A., Forgues, M., & Wang, X. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0908 · Cited by 446 · cited 11×
“(32) Aberrant b-catenin activation is frequently detected in human HCCs and correlates with HCC dedifferentiation.”
BackgroundInfluentialSelf-citationPtpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Bard-Chapeau, E. A., Li, S., Ding, J., Zhang, S. S., Zhu, H. H., Princen, F., Fang, D. D., Han, T., Bailly-Maitre, B., Poli, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.023 · Cited by 332
Self-citationThe Tyrosine Phosphatase Shp2 in Development and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06002-1 · Cited by 277 · cited 1×
“In addition, genetic and sequencing data have indicated a broad role for Shp2 in development and disease.((12,13)) Ptpn11 mutation was detected in up to 50% of Noonan syndrome patients who possessed a high risk of leukemia.”
BackgroundDirect Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis
Song, G., Pacher, M., Balakrishnan, A., Yuan, Q., Tsay, H.-C., Yang, D., Reetz, J., Brandes, S., Dai, Z., Pützer, B. M., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.01.010 · Cited by 208 · cited 1×
“The uptake of ammonia for the production of urea is a unique function of hepatocytes.((34)) Welldifferentiated HCC cells could, to some extent, exert this hepatic function, while poorly differentiated HCC cells largely lose this ability.”
BackgroundBile Acids Activate YAP to Promote Liver Carcinogenesis
Anakk, S., Bhosale, M., Schmidt, V. A., Johnson, R. L., Finegold, M. J., & Moore, D. D. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.030 · Cited by 196
Cited by
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
Lee, T. K.-W., Guan, X.-Y., & Ma, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00508-3 · Cited by 460
Self-citationPrecision diagnosis and treatment of liver cancer in China
Fu, J., & Wang, H. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.10.008 · Cited by 301
Self-citationWang, J., Yu, H., Dong, W., Zhang, C., Hu, M., Ma, W., Jiang, X., Li, H., Yang, P., & Xiang, D. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.041 · Cited by 277
Self-citationTargeted therapy for hepatocellular carcinoma: Challenges and opportunities
Chen, S., Cao, Q., Wen, W., & Wang, H. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.114428 · Cited by 255
Self-citationSong, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107966 · Cited by 125
Metadata
- Authors
- Xiang, D., Cheng, Z., Liu, H., Wang, X., Han, T., Sun, W., Li, X., Yang, W., Chen, C., Xia, M., Liu, N., Yin, S., Jin, G., Lee, T., Dong, L., Hu, H., Wang, H., & Ding, J.
- Venue
- Hepatology
- Published
- 2017-01-06
- Volume
- 65
- Issue
- 5
- Pages
- 1566-1580
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2548545914
- Cited by
- 142
- References
- 8
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients. https://app.cochat.ai/papers/10.1002/hep.28919
- The paper
- Xiang, D., Cheng, Z., Liu, H., Wang, X., Han, T., Sun, W., Li, X., Yang, W., Chen, C., Xia, M., Liu, N., Yin, S., Jin, G., Lee, T., Dong, L., Hu, H., Wang, H., & Ding, J. (2017). Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients. Hepatology. https://doi.org/10.1002/hep.28919
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.